Delivery Order SPE2DR25D3401-SPE2DR26FL0FH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,416.40 to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Insulin Aspart 100 Unit/mL in 10mL vials. This is a firm fixed-price delivery order with an ultimate completion date of December 1, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued as a child contract...
- The U.S. Department of Defense's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,463.20 for Insulin Aspart 100 Unit/mL vials (10mL) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a $1,023.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10 mL) on July 14, 2025, with an ultimate completion date of July 15, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The place of...
- The Defense Logistics Agency has awarded a delivery order valued at $2,671.90 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/ML in 10 ML vials. This firm fixed price delivery order, issued on December 5, 2025, with an ultimate completion date of December 8, 2025, represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The award is unset-aside and competitively awarded, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL) with a ceiling value of $1,463.20. This is a firm fixed price delivery order with an ultimate completion date of October 24, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a $3,736.48 delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Insulin Aspart 100 Unit/mL in 10mL vials. The award represents a competitive, non-set-aside contract with firm fixed pricing and a completion date of December 12, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) with a ceiling value of $1,454.62. This non-set-aside competitive award was issued on November 20, 2025, with an ultimate completion date of November 21, 2025, and will be performed at the vendor's Conshohocken, Pennsylvania facility. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 7, 2025, for the supply of Insulin Aspart 100 Unit/mL vials in 10mL quantities, with a ceiling value of $1,257.13 and an ultimate completion date of December 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency awarded a $4,196.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10mL) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $4,205.06 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) on August 28, 2025, with completion scheduled for August 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract is classified as a child award under AmerisourceBergen's larger Indefinite...
- SPE2DR25D3401Indefinite Delivery Contract
- SPE2DR25D3401-SPE2DR26FL0FHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,699.68 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL in 10mL vials. This non-competitive, firm fixed price delivery order was awarded on December 1, 2025, with an ultimate completion date of December 2, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion master contract running through December 2026 that serves as the primary pharmaceutical supply vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other military healthcare systems. The company's extensive federal contracting history demonstrates its capability to supply a comprehensive range of pharmaceutical products including specialty medications, generic drugs, vaccines, and medical devices across multiple therapeutic domains. This insulin delivery order supports ongoing military medical supply requirements through the established prime vendor relationship, enabling efficient procurement of essential diabetes management pharmaceuticals for military personnel and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 11/30/25 |